Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer

A proof-of-concept study of ODM-201 in patients with progressive castration-resistant prostate cancer

Too few women being offered breast-conserving treatment?

Personalised medicine: Hype or hope?

Awareness of personalised medicine in cancer patients

BRAF inhibitor dabrafenib alone vs combination with MEK1/2 inhibitor trametinib for melanoma

Phase I and II trials focus on drug combination slowing development of resistance inhibiting BRAF

Gefitinib versus placebo in oesophageal cancer progressing after chemotherapy

Biomarker analysis of MISSION: EGFR lung tumours may benefit from sorafenib

Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer – Phase III MISSION trial

Key topics from day 2 of the 10th International Workshop on Non-Hodgkin's Lymphoma

iwNHL 10: Advances in the treatment of lymphoma